Clinical Chemistry and Laboratory Medicine (CCLM) · 2021 · 41 citations · 50 references
MedicineInfectious DiseasesMolecular MedicineEarly DetectionMolecular VirologyVirologyAntigen Detection AssaysInfectious Disease Molecular TestingNucleic Acid Amplification TestingRapid Diagnostic TestsRespiratory InfectionsRespiratory Infectious DiseasesImmunoassaysNucleic Acid AmplificationPoint-of-care Antigen TestingRapid Antigen Detection TestingRapid Antigen TestingRapid Antigen TestsRapid Screening TestsViral Antigen Detection
With an almost unremittent progression of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infections all around the world, there is a compelling need to introduce rapid, reliable, and high-throughput testing to allow appropriate clinical management and/or timely isolation of infected individuals. Although nucleic acid amplification testing (NAAT) remains the gold standard for detecting and theoretically quantifying SARS-CoV-2 mRNA in various specimen types, antigen assays may be considered a suitable alternative, under specific circumstances. Rapid antigen tests are meant to detect viral antigen proteins in biological specimens (e.g. nasal, nasopharyngeal, saliva), to indicate current SARS-CoV-2 infection. The available assay methodology includes rapid chromatographic immunoassays, used at the point-of-care, which carries some advantages and drawbacks compared to more conventional, instrumentation-based, laboratory immunoassays. Therefore, this document by the International Federation for Clinical Chemistry and Laboratory Medicine (IFCC) Taskforce on COVID-19 aims to summarize available data on the performance of currently available SARS-CoV-2 antigen rapid detection tests (Ag-RDTs), providing interim guidance on clinical indications and target populations, assay selection, and evaluation, test interpretation and limitations, as well as on pre-analytical considerations. This document is hence mainly aimed to assist laboratory and regulated health professionals in selecting, validating, and implementing regulatory approved Ag-RDTs.
50
Characterization of a Novel Coronavirus Associated with Severe Acute Respiratory Syndrome
Paul A. Rota, M. Steven Oberste, Stephan S. Monroe et al. · Science · 2003 · 2.6K citations · Full text
Proteomics of SARS-CoV-2-infected host cells reveals therapy targets
Denisa Bojková, Kevin Klann, Benjamin Koch et al. · Nature · 2020 · 1.1K citations · Full text